Literature DB >> 19673675

Genetic determinants of response to statins.

Bas J M Peters1, Olaf H Klungel, Anthonius de Boer, Anke-Hilse Maitland-van der Zee.   

Abstract

In developed countries, cardiovascular disease is one of the leading causes of death. Statins are abundantly prescribed to reduce the risk of coronary artery disease by lowering cholesterol. Genetic factors are thought to be partly responsible for the interindividual variation in the response to statins. This article reviews the most important studies conducted on pharmacogenetics of statins. Currently, there is no evidence to advocate pharmacogenetic testing before initiating therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673675     DOI: 10.1586/erc.09.83

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  4 in total

1.  Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.

Authors:  Bas J M Peters; Helmi Pett; Olaf H Klungel; Bruno H Ch Stricker; Bruce M Psaty; Nicole L Glazer; Kerri L Wiggins; Josh C Bis; Anthonius de Boer; Anke-Hilse Maitland-van der Zee
Journal:  Atherosclerosis       Date:  2011-06-17       Impact factor: 5.162

2.  Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala.

Authors:  Lakshmi Mahadevan; Ancy Yesudas; P K Sajesh; S Revu; Prasanna Kumar; Devi Santhosh; Sam Santhosh; J M Sashikumar; V K Gopalakrishnan; Joji Boben; Changanamkandath Rajesh
Journal:  Indian J Hum Genet       Date:  2014-04

3.  Molecular mechanisms of statin intolerance.

Authors:  Anna Gluba-Brzozka; Beata Franczyk; Peter P Toth; Jacek Rysz; Maciej Banach
Journal:  Arch Med Sci       Date:  2016-05-18       Impact factor: 3.318

4.  Pharmacogenomic insights into treatment and management of statin-induced myopathy.

Authors:  Bas Jm Peters; Olaf H Klungel; Frank L Visseren; Anthonius de Boer; Anke-Hilse Maitland-van der Zee
Journal:  Genome Med       Date:  2009-12-29       Impact factor: 11.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.